WHO AWaRe

Logo of the WHO Aware Classification

The WHO AWaRe Classification is a method to categorize antibiotics into three groups in an effort to improve appropriate antibiotic use.[1][2] The classification is based, in part, on the risk of developing antibiotic resistance and their importance to medicine.[1][3] It does not reflect effectiveness or strength.[4] It is accompanied by a book, The WHO AWaRe antibiotic book, that outlines which and how to use antibiotics in 34 common infections.[5]

The three groups are "access", meaning use can be unrestricted, "watch", meaning care should be taken, and "reserve" meaning use should be saved for cases in which other options are not possible.[3] The recommendation is that greater than 60% of antibiotics used within a country come from the "access" group.[6]

The classification was developed by the World Health Organization (WHO) and launched in 2017.[1] It is an aspect of the WHO Model List of Essential Medicines.[3] The classification as of 2021 covers 258 items.[1] Challenges in its implementation include lack of awareness, little political will, and few resources.[6]

## Contents

* 1 Classification
* 1.1 Access
* 1.2 Watch
* 1.3 Reserve
* 1.4 Not recommended
* 2 See also
* 3 References
* 4 External links

## Classification[edit | edit source]

### Access[edit | edit source]

Antibiotics in the access group have a lower risk of antibiotic resistance and are typically recommended as first- and second-line treatments of infections.[6][7] They are generally inexpensive and safe.[3] They should be readily available when needed, and are highlighted in green.[7][3] Access group antibiotics include amikacin, amoxicillin, amoxicillin/clavulanic acid, ampicillin, benzylpenicillin, cefalexin, chloramphenicol, clindamycin, doxycycline, and nitrofurantoin.[5] Nearly 60% can be taken by mouth.[4]

### Watch[edit | edit source]

Antibiotics in the watch group are typically broad-spectrum antibiotics with a greater risk of resistance.[6] They are generally only recommended if other options are not possible.[3] They should be used carefully to save their effectiveness for those cases in which "access" antibiotics are not appropriate.[7] Costs are also generally greater, and they are highlighted in yellow.[3] Included in this category are azithromycin, several cephalosporins, ciprofloxacin, clarithromycin, and vancomycin.[5] About 40% are available by mouth.[4]

### Reserve[edit | edit source]

The reserve group, generally taken from the WHO Model List of Essential Medicines, are generally last line options and used for infections not treatable by other antibiotics, ie multi-drug-resistant organisms.[5] They are highlighted in red.[3] Include in this category are ceftazidime/avibactam, colistin, polymyxin B (by mouth and by injection), and linezolid.[1][5] The intravenous formulation of fosfomycin is reserve while the by mouth formulation is watch.[1] About 10% of this group is available by mouth.[4]

### Not recommended[edit | edit source]

An occasionally included fourth group defines antibiotics whose use is not recommended.[3]

## See also[edit | edit source]

* List of WHO AWaRe antibiotics

## References[edit | edit source]

1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "2021 AWaRe classification". www.who.int. Archived from the original on 3 August 2023. Retrieved 16 August 2023.
2. ↑ "2.3.5. WHO model lists of essential medicines". WHO Expert Committee on Biological Standardization: seventy-sixth report. Geneva: World Health Organization. 2023. pp. 17–18. ISBN 978-92-4-007448-4. Archived from the original on 2023-11-19. Retrieved 2023-11-17.
3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 The WHO AWaRe (Access, Watch, Reserve) antibiotic book. 9 December 2022. Archived from the original on 13 August 2023. Retrieved 16 August 2023.
4. ↑ 4.0 4.1 4.2 4.3 "WHO Antibiotics Portal". aware.essentialmeds.org. Archived from the original on 7 August 2023. Retrieved 20 November 2023.
5. ↑ 5.0 5.1 5.2 5.3 5.4 Zanichelli, Veronica; Sharland, Michael; Cappello, Bernadette; Moja, Lorenzo; Getahun, Haileyesus; Pessoa-Silva, Carmem; Sati, Hatim; van Weezenbeek, Catharina; Balkhy, Hanan; Simão, Mariângela; Gandra, Sumanth; Huttner, Benedikt (1 April 2023). "The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance". Bulletin of the World Health Organization. 101 (4): 290–296. doi:10.2471/BLT.22.288614. ISSN 0042-9686. Archived from the original on 7 May 2023. Retrieved 17 November 2023.
6. ↑ 6.0 6.1 6.2 6.3 Mudenda, Steward; Daka, Victor; Matafwali, Scott K. (2023). "World Health Organization AWaRe framework for antibiotic stewardship: Where are we now and where do we need to go? An expert viewpoint". Antimicrobial stewardship & healthcare epidemiology: ASHE. 3 (1): e84. doi:10.1017/ash.2023.164. ISSN 2732-494X. PMID 37179758. Archived from the original on 2023-05-14. Retrieved 2023-11-18.
7. ↑ 7.0 7.1 7.2 World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

## External links[edit | edit source]

* List by the WHO Archived 2023-06-14 at the Wayback Machine
* The WHO AWaRe (Access, Watch, Reserve) antibiotic book. 9 December 2022. Archived from the original on 13 August 2023. Retrieved 16 August 2023.